Cure My Disease

Don't miss your cure!

 Log in / Sign up

Clotting clues: simple blood test eyed to catch sepsis before it turns deadly

NCT ID NCT07073456

NEW Diagnosis Sponsor: Hellenic Institute for the Study of Sepsis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers want to know whether a bedside device that measures how blood clots can predict which patients with an infection will develop sepsis. The study enrolls 147 adults arriving at an emergency department with a suspected infection. Everyone gives blood for the clotting monitor and standard lab tests, with daily clotting readings for three days if they are admitted. The goal is to see whether any clotting measurement differs between patients who go on to develop sepsis within 72 hours and those who do not.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Viscoelastic Coagulation Monitor (VCM) blood test
What this could lead to
If it works, emergency doctors could use a quick bedside clotting test to flag which infected patients are sliding toward sepsis, so treatment starts sooner.
What could go wrong
This is an early, single-hospital observational study of 147 people, so it can only show a link between clotting readings and sepsis, not prove the test saves lives. Results may not hold in other hospitals or patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

147 people

The number who actually took part.

Started

Oct 2024

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients, presenting to the Emergency Department of the General Hospital of Attikon, who meet all inclusion criteria and who do not meet any exclusion criterion will be enrolled in the study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults male or female (age 18 years or more) * Suspicion of infection, defined according to medical judgment Exclusion Criteria: * Age less than 18 years * Denial for consent * Intake of any anti-coagulant medication the last one month * Intake of any anti-platelet medication the last one month * Intake of any biological disease modifying anti-rheumatic medication the last one month * Medical history of inflammatory bowel disease or pulmonary hypertension * Any medical history of hemophilia or congenital coagulation disorders * Any known solid tumor or hematologic malignancy irrespective the stage and treatment * Known infection by the hepatitis viruses B and C * Known infection by the human immunodeficiency virus * Pregnancy or lactation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Infection are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Infections infectious disease infectious disease with sepsis Sepsis thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Infection Sepsis

Contacts and locations

Locations

  • 4th Department of Internal Medicine, "Attikon" University Hospital, National and Kapodistrian University of Athens, Medical School

    Chaïdári, Attica, 12462, Greece

  • Emergency Medicine Department, Attikon University Hospital, NKUA

    Chaïdári, 12462, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.